Bragar Eagel & Squire Investigates Potential Claims Against Aquestive (AQST)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 20 2026
0mins
Source: Globenewswire
- Legal Investigation Launched: Bragar Eagel & Squire, P.C. is investigating Aquestive Therapeutics, Inc. for potential violations of federal securities laws, which may impact shareholder rights.
- FDA Notice Impact: On January 9, 2026, Aquestive received a notice from the FDA indicating deficiencies in its New Drug Application, leading to a stock price drop and investor losses.
- Investor Rights Protection: The law firm encourages all investors who purchased or held Aquestive shares during this period to contact them to explore potential legal options and rights.
- No-Cost Consultation: Bragar Eagel & Squire offers no-cost legal consultations aimed at assisting affected shareholders in understanding their rights and potential claims.
Analyst Views on AQST
Wall Street analysts forecast AQST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AQST is 8.40 USD with a low forecast of 8.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.240
Low
8.00
Averages
8.40
High
10.00
Current: 3.240
Low
8.00
Averages
8.40
High
10.00
About AQST
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
